CLINICAL_TRIALS
trial_result
· 2015-05-01
Clinical Trial Update: Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors [Phase 1]
Summary
This update reports the completion of a Phase 1 trial of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SCRI Development Innovations, LLC | Conditions: Malignant Solid Tumour | Phase 1 | Status: COMPLETED